574 results on '"Barosi, G."'
Search Results
2. SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias
3. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
4. JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
5. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
6. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
7. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
8. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
9. How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?
10. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
11. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms
12. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
13. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
14. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
15. Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis
16. Mutations and prognosis in primary myelofibrosis
17. 1873P Patients with myeloproliferative neoplasms and self-care behaviours: Preliminary data of a cross-sectional study
18. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
19. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
20. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
21. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
22. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
23. Strategies for dissemination and implementation of guidelines
24. Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
25. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis
26. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
27. Consensus-based definition of unfitness to intensive and nonintensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
28. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
29. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation
30. Recurrent cytogenetic abnormalities in ex vivo expanded late passage MSCs from patients with myeloproliferative neoplasms: P1084
31. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
32. Inadequate erythropoietin response to anemia: definition and clinical relevance
33. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A
34. Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios
35. MYELOFIBROSIS WITH MYELOID METAPLASIA (MMM) IN YOUNG INDIVIDUALS: DISEASE CHARACTERISTICS, PROGNOSTIC FACTORS AND IDENTIFICATION OF RISK GROUPS
36. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology
37. Erratum: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
38. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
39. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
40. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
41. HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY
42. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation
43. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
44. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia
45. Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism
46. Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia)
47. The plasma59Fe clearance curve in man: An evaluation of methods of measurement and analysis
48. Cardiovascular events and intensity of treatment in polycythemia vera
49. Regulatory mRNA/microRNA networks in CD34+ cells from Primary Myelofibrosis
50. An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.